Fujisawa Pharmaceutical Company, Ltd.

Sumio Kiyoto

Masakuni Okuhara

Motoaki Nishikawa

Masanobu Kohsaka

Shigehiro Takase

Satoshi Okada

Masami Ezaki

Tohru Kino

Nobuharu Shigematsu

Hiroshi Terano

Hidetsugu Murai

Hirokazu Tanaka

Keiji Hemmi

Hiroshi Imanaka

Hatsuo Aoki

Morita Iwami

Yasuhisa Tsurumi

Nobutaka Oohata

Eiko Kino

The novel peptides WS-9326A, WS-9326B, their derivatives and pharmaceutically acceptable salts thereof have useful pharmacological activities, particularly in the treatment and/or prevention of asthma and/or pain. A method for the production of the peptides WS-9326A and WS-9326B and derivatives thereof using Streptomyces violaceoniger No. 9326 in a biologically pure form is described herein.

Process for producing WS-9326A and WS-9326B

This invention relates to the novel peptides WS-9326A, WS-9326B, their derivatives and pharmaceutically acceptable salts thereof which have pharmacological activities, particularly in the treatment and/or prevention of asthma and/or pain.

Peptides WS-9326a and WS-9326b, derivatives thereof and uses thereof

Anthraquinone compounds of the formula: ##STR1## wherein: R.sup.1 is hydrogen, hydroxy or acyloxy,

Anthraquinone derivatives and preparation thereof

The invention relates to a pharmaceutical composition for treating lymphocytic leukemia, melanoma or mammary carcinoma comprising an effective amount of FR-900216.

Antitumor agent comprising FR-900216

The invention relates to a new compound, designated FR-68504. The compound has antitimor activities and is effective in the treatment of various tumors in both human beings and animals. There is also provided a process for preparing FR-68504 compound which comprises culturing a FR-68504 producing strain belonging to the genus Amauroascus in a nutrient medium. Pharmaceutical composition comprising FR-68504 as an active ingredient is also described.

Compound FR-68504, production thereof and use thereof

Novel compounds designated as WS 6049-A and WS 6049-B are disclosed, as well as compositions containing the compounds thereof, a method of treating microbial infections, a method of prolonging the survival time of the patient with lymphocytic leukemia by administering the compounds thereof, and a process for making the WS 6049 substances, are disclosed. As indicated above, the novel compounds have antimicrobial and antileukemic activities which make them useful against a variety of pathogenic microorganisms and leukemic tumors.

Biologically active WS 6049 substances, a process for the production

Growing community of inventors

Tsukuba, Japan

Sumio Kiyoto